FindTrial
Sign In

Head-to-head comparison of 68Ga-FAPI PET/CT versus 18F-FDG PET/CT in fumarate hydrate deficient renal cell carcinoma: a prospective, single-center, non-interventional clinical study

Head-to-head comparison of 68Ga-FAPI PET/CT versus 18F-FDG PET/CT in fumarate hydrate deficient renal cell carcinoma: a prospective, single-center, non-interventional clinical study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072818
Enrollment
Unknown
Registered
2023-06-26
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fumarate hydrate deficient renal cell carcinoma

Interventions

Gold Standard:18FDG PET/CT
Index test:68Ga-FAPI PET/CT

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) FHRCC confirmed by pathology or gene sequencing; 2) without any treatment within 4 weeks before PET examination; 3) Age = 18 years old

Exclusion criteria

Exclusion criteria: 1) Patients during pregnancy/lactation; 2) Patients complicated with other malignant tumors; 3) Patients who can not sign the scanned informed consent.

Design outcomes

Primary

MeasureTime frame
Sensitivity;specificity;—

Countries

China

Contacts

Public ContactRui Huang

West China Hospital of Sichuan University

huang_rui@scu.edu.cn+86 189 8060 5781

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026